Adma Biologics Stock Market Value
| ADMA Stock | USD 16.09 0.50 3.21% |
| Symbol | ADMA |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ADMA Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 0.86 | Revenue Per Share | Quarterly Revenue Growth 0.12 | Return On Assets | Return On Equity |
ADMA Biologics's market price often diverges from its book value, the accounting figure shown on ADMA's balance sheet. Smart investors calculate ADMA Biologics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since ADMA Biologics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that ADMA Biologics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ADMA Biologics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ADMA Biologics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ADMA Biologics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ADMA Biologics.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in ADMA Biologics on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding ADMA Biologics or generate 0.0% return on investment in ADMA Biologics over 90 days. ADMA Biologics is related to or competes with ACADIA Pharmaceuticals, Praxis Precision, Belite Bio, Ligand Pharmaceuticals, Soleno Therapeutics, Mirum Pharmaceuticals, and Dyne Therapeutics. ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-... More
ADMA Biologics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ADMA Biologics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ADMA Biologics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.51 | |||
| Information Ratio | 0.0272 | |||
| Maximum Drawdown | 14.85 | |||
| Value At Risk | (4.24) | |||
| Potential Upside | 4.86 |
ADMA Biologics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ADMA Biologics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ADMA Biologics' standard deviation. In reality, there are many statistical measures that can use ADMA Biologics historical prices to predict the future ADMA Biologics' volatility.| Risk Adjusted Performance | 0.0495 | |||
| Jensen Alpha | 0.0927 | |||
| Total Risk Alpha | (0.07) | |||
| Sortino Ratio | 0.0298 | |||
| Treynor Ratio | 0.1922 |
ADMA Biologics February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0495 | |||
| Market Risk Adjusted Performance | 0.2022 | |||
| Mean Deviation | 2.1 | |||
| Semi Deviation | 2.37 | |||
| Downside Deviation | 2.51 | |||
| Coefficient Of Variation | 1900.13 | |||
| Standard Deviation | 2.75 | |||
| Variance | 7.56 | |||
| Information Ratio | 0.0272 | |||
| Jensen Alpha | 0.0927 | |||
| Total Risk Alpha | (0.07) | |||
| Sortino Ratio | 0.0298 | |||
| Treynor Ratio | 0.1922 | |||
| Maximum Drawdown | 14.85 | |||
| Value At Risk | (4.24) | |||
| Potential Upside | 4.86 | |||
| Downside Variance | 6.31 | |||
| Semi Variance | 5.62 | |||
| Expected Short fall | (2.38) | |||
| Skewness | 0.4536 | |||
| Kurtosis | 0.8907 |
ADMA Biologics Backtested Returns
At this point, ADMA Biologics is not too volatile. ADMA Biologics secures Sharpe Ratio (or Efficiency) of 0.0399, which signifies that the company had a 0.0399 % return per unit of return volatility over the last 3 months. We have found twenty-eight technical indicators for ADMA Biologics, which you can use to evaluate the volatility of the firm. Please confirm ADMA Biologics' Risk Adjusted Performance of 0.0495, semi deviation of 2.37, and Mean Deviation of 2.1 to double-check if the risk estimate we provide is consistent with the expected return of 0.1%. ADMA Biologics has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.7, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, ADMA Biologics' returns are expected to increase less than the market. However, during the bear market, the loss of holding ADMA Biologics is expected to be smaller as well. ADMA Biologics at this time shows a risk of 2.55%. Please confirm ADMA Biologics treynor ratio, downside variance, and the relationship between the total risk alpha and value at risk , to decide if ADMA Biologics will be following its price patterns.
Auto-correlation | -0.5 |
Modest reverse predictability
ADMA Biologics has modest reverse predictability. Overlapping area represents the amount of predictability between ADMA Biologics time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ADMA Biologics price movement. The serial correlation of -0.5 indicates that about 50.0% of current ADMA Biologics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.5 | |
| Spearman Rank Test | -0.31 | |
| Residual Average | 0.0 | |
| Price Variance | 0.65 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:Check out ADMA Biologics Correlation, ADMA Biologics Volatility and ADMA Biologics Performance module to complement your research on ADMA Biologics. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
ADMA Biologics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.